Immunohistochemical Detection of p53 Oncoprotein in Human Oral Squamous Cell Carcinomas and Leukoplakias: Comparison with Proliferating Cell Nuclear Antigen Staining and Correlation with Clinicopathological Findings

Nishioka, Hiroki; Hiasa, Yoshio; Hayashi, Isao; Kitahori, Yoshiteru; Konishi, Noboru; Sugimura, Masahito

doi:10.1159/000227223

Cited by 48 publications

(36 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Analysis of NLNR status showed no differences. Other data published evaluating the relationships between p-53 and TNM-stage, G-stage, tumor size and site, age and sex did not reveal any dependencies [1,13,21], although some studies have suggested such correlations [5,15,16]. The lack of TNM stage correlation with p-53 in our present study can reflect the number of subjects in a particular stage.…”

Section: Discussioncontrasting

confidence: 68%

“…Others have demonstrated PCNA overexpression in precancerous lesions as well as in carcinomas in situ, progressing to invasive SCC [14,16]. We would speculate that in patients with LR after TL and initially negative lymph nodes the epithelium adjacent to the neoplasm underwent loss of control of cell proliferation.…”

Section: Discussionmentioning

confidence: 79%

“…As shown in Table 2, a similar tendency was present in the other two comparisons. Other published data have demonstrated positive p-53 staining in pre-cancerous lesions [11,16,25] and in normal epithelium adjacent to a neoplasm [19,20,25]. The higher percentage of p-53 stained in the subgroup with local recurrences with histologically confirmed negative margins suggests that the epithelium surrounding the tumor could be in the process of malignant transformation.…”

Section: Discussionmentioning

confidence: 91%

See 2 more Smart Citations

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer

Morawski¹,

Gabriel

Namysłowski³

et al. 1999

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

The authors assessed proliferating cell nuclear antigen (PCNA), p-53 oncoprotein and morphologic tumor front grading (TFG) in patients with advanced squamous cell carcinoma (SCC), of the larynx and a poor prognosis and tried to find a correlation with tumor stage, the Broders grading system, local and neck lymph node metastases, as well as nodal and local recurrences. In addition, utility of the parameters investigated was evaluated in developing a prognostic factor model, using uni- and multivariate Cox regression analysis. Included in this study were 54 patients (mean age 57 years +/- 8.6). PCNA-positive staining was found in all but one patient with advanced disease, while p-53 stained positively in only 24 subjects (44.4%). The PCNA index ranged from 4.6 to 59.0% (mean, 23.4 +/- 11. 0) and the p-53 index varied from 4.0 to 42.0% (mean, 17.2 +/- 8.6). The TFG score ranged from 9 to 23 points (mean, 15.1 +/- 3.2). PCNA, p-53 and TFG were found to be the markers that provided significant additional information about the biological behavior of tumor cells. The high variability of the results (PCNA, p-53) and high percentage of negatively stained cells (p-53) reduced their application in clinical use. PCNA correlated with tumor grade, G (r = 0.38; P < 0. 01), but negatively with nodal (N) disease(r = -0.37; P < 0.01). The mean values of PCNA and p-53 index were higher in the subgroup with local recurrences. Our present attempt to develop a useful prognostic factor model failed.

show abstract

Section: Discussioncontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer

Morawski¹,

Gabriel

Namysłowski³

et al. 1999

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

show abstract

“…The functional inactivation of p53 protein plays a crucial role in the malignant transformation process. It provides the tumor cell with a higher capacity for division and proliferation [11]. A total of 21-49% of endometrial carcinomas show abnormal p53 expression [12,13].…”

Section: Introductionmentioning

confidence: 99%

p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

Appel

Edelweiss

Fleck

et al. 2008

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The objective of this study was to verify the frequency of p53 and BCL-2 immunohistochemical expression in patients with endometrial carcinoma and to correlate it with histological factors (histological type, tumor grade, depth of myometrial invasion, lymph node involvement and surgical staging) and survival. Forty-eight patients with endometrial carcinoma who were submitted to primary surgical treatment were assessed. p53 and BCL-2 immunohistochemical expression was determined using paraffin blocks containing the tumor area. p53 and BCL-2 expression was detected in 39.6% and 58.3% of the tumors, respectively. No significant difference was found regarding the frequency of p53 expression when analyzing histological type (33.3% in endometrioid tumors, 58.3% in non-endometrioid tumors; p = 0.176), depth of myometrial invasion (p = 0.632) and surgical staging (I-11.1%, II-66.7%, III-57.1%; p = 0.061). p53 expression was significantly more frequent in undifferentiated tumors (p = 0.007) and in those showing lymph node involvement (p = 0.030). Univariate analysis showed a positive association with death (RR, 3.358; CI, 1.386-8.134; p = 0.005) and short-term survival. The present study did not reveal any correlation between BCL-2 expression and histopathologic markers or survival. In conclusion, this study showed that p53 expression is directly correlated with undifferentiated tumors, lymph-node involvement and risk of death. On the other hand, BCL-2 expression was not correlated with any known histological factors.

show abstract

“…p53 expres sion was not related to the percentage of PCNA-labeled cells in this study. Some investigators have reported that p53 is correlated with PCNA [31][32][33][34][35][36]. Conversely, other groups found that there is no correlation between p53 and PCNA expression [37,38], The relationship between PCNA and p53 as shown by immunohistochemical analy sis remains controversial.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Defection of Proliferating Cell Nuclear Antigen and p53 Expression in Carcinoma of the Extrahepatic Bile Duct

Sakai¹,

Sugai

Nakamura

et al. 1997

Oncology

View full text Add to dashboard Cite

We used an immunohistochemical method to determine the concentrations of p53 and proliferating cell nuclear antigen (PCNA) to evaluate their usefulness as a predictor of malignancy and examined the relationship between PCNA and p53 in carcinomas of the extrahepatic bile duct (EHBD). Paraffin-embedded specimens from 46 patients were immunostained for PCNA and p53 using PC 10 and D07 monoclonal antibodies, respectively. The PCNA labeling index (LI) was closely associated with the stages of the tumor and depth of invasion (p < 0.05). The cumulative survival rate of patients with a low PCNA LI (LI < 47%) was found to be significantly better than that of patients with a high PCNA LI (LI ≥47%) in all cases and patients with advanced cancer by univariate analysis (p < 0.05), but PCNA LI was not an independent prognostic factor in multivariate analysis. We detected p53 in 37% of the EHBD cancers. We also found that p53 positivity was not related to the percentage of PCNA-labelled cells or survival. The results suggest that PCNA immunoreactivity may be a useful predictor of malignancy in patients with EHBD carcinomas.

show abstract

Immunohistochemical Detection of p53 Oncoprotein in Human Oral Squamous Cell Carcinomas and Leukoplakias: Comparison with Proliferating Cell Nuclear Antigen Staining and Correlation with Clinicopathological Findings

Cited by 48 publications

References 3 publications

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer

Clinical application of proliferating cell nuclear antigen, oncoprotein p53 and tumor front grading analysis in patients operated on for laryngeal cancer

p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

Immunohistochemical Defection of Proliferating Cell Nuclear Antigen and p53 Expression in Carcinoma of the Extrahepatic Bile Duct

Contact Info

Product

Resources

About